Combination regimen of cladribine (2-Chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia

Leukemia and Lymphoma

Volumn 39, Issue 1-2, 2000, Pages 121-129

  Robak, T ^a   Wrzesien Kus, A ^a   Lech Maranda, E ^a   Kowal, M ^a   Dmoszynska, A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute myeloid leukemia; Cladribine; Cytosine arabinoside; G CSF; Resistant or relapsing patients

Indexed keywords

CLADRIBINE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLERGY; ALOPECIA; ARTICLE; BONE MARROW; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VOMITING;

EID: 0033846491     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009053545     Document Type: Article

References (25)

1. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
2. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
3. Acute myeloid leukemia
4. Treatment of resistant disease
5. Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor prognosis myeloid leukemias
6. Response to salvage therapy and survival after relapse in acute myelogenous leukemia
7. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia
8. Fludarabine-present status and future developments in chronic lymphocytic leukemia and lymphoma
9. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity
10. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia
11. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults
12. Use of G-CSF before, during and after fludarabine plus Ara-C induction therapy of newly diagnosed AML or MDS: Comparison with fludarabine + Ara-C without G-CSF
13. FLAG (fludarabine + high dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of ″poor risk″ acute myeloid leukemias
14. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group
15. Report of the national cancer institute sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
16. Regrowth resistance in leukemia and lymphoma. the need for a new system to classify treatment failure and for new approaches to treatment
17. Toxicity and response criteria for the Eastern cooperative oncology group
18. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
19. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF): An effective remission -induction therapy for poor -prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a phase II trial
20. Complete hematologic remissions induced by 2-Chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia
21. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia pharmacokinetic, pharmacodynamic and molecular interactions
22. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
23. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukemia
24. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia
25. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients